Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Tess Cameron
Semper Maior: Spirits Rising — RApport
January 4, 2024 With an insane amount of data analysis and insights by Alex Martinez-Forte, Jacqueline Rhuda, and Kris Shuman, and a massive graphics effort by Erin Clutter. * * * A year ago we published the first “Semper Maior” piece, making the case that biotech was on firm ground and ready for a reboot. We put out the second piece last summer, when it felt like the rebound was underway. Had the year ended in October or even November… well, you know.
Act now to prevent SVB’s failure from becoming a national crisis — RApport
By Kyle Teamey, Josh Resnick, Tess Cameron, and Peter Kolchinsky Kyle Teamey is Managing Partner, Planetary Health, at RA Capital Management. Josh Resnick is Managing Director at RA Capital Management. Tess Cameron is Principal, Strategic Finance, at RA Capital Management. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal.
We shut down our SPAC — here’s why — RApport
By Tess Cameron and Matthew Hammond Tess Cameron is a Principal in Strategic Finance and Matthew Hammond is a Principal on the Investment Team at RA Capital. December 20, 2022 2020 and 2021 were the heyday for special purpose acquisition companies, or SPACs. We got in on the act ourselves – twice! – and we’ve learned a lot about why SPACs can sometimes work for a biotech in very particular circumstances, but also why mostly they don’t.
Alnylam is doing what the IRA is telling it to do — RApport
Amvuttra was approved in June 2022. It’s an siRNA, which means the IRA treats it like a small molecule, since it was approved via the NDA pathway. So under the IRA it would get nine years before Medicare’s price setting kicks in but only if it qualifies for and is selected for ‘negotiation’.
2020 biotech IPOs shatter all the records
BIOBUSINESS BRIEFS 20 January 2021 Nature Reviews Drug Discovery 20, 93-94 (2021) Competing Financial Interests RA Capital is a registered investment adviser. This article is not intended, and should not be construed as, investment advice or recommendation to invest in any security. Likewise, this article is not intended as a solicitation to invest in any RA Capital product or service. RA Capital may hold long and/or short positions in companies referenced.
Saving the most vulnerable from COVID-19
Home Life Health Article Much emphasis has been placed on building lab capacity for polymerase chain reaction tests, the gold standard for detecting the COVID-19 virus A woman wearing a mask shops at Portobello Road Market, following the outbreak of the coronavirus disease (COVID-19), London, Britain, June 1, 2020.
Saving the most vulnerable from Covid-19 pandemic
By Simon Johnson, Galit Alter, Tess Cameron, and Michael Mina Cambridge In Massachusetts, which has a population of close to 7mn, over 6,000 people have died from Covid-19 since the beginning of March. But one relatively small group – including about 38,000 people, or 0.5% of the state’s population – accounts for 60% of these deaths.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Tess
Contact Tess, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack